XML 37 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Impact of ASC 326 adoption
Preferred Stock
Common Stock
Additional paid-in capital
Unearned compensation
Retained (deficit) earnings
Retained (deficit) earnings
Impact of ASC 326 adoption
Accumulated other comprehensive (loss) income
Treasury stock
Beginning balance, preferred stock (in shares) at Dec. 31, 2019     522,000              
Beginning balance, common stock (in shares) at Dec. 31, 2019       49,585,000            
Beginning balance at Dec. 31, 2019 $ 1,758,564 $ (24,380) $ 40,633 $ 517 $ 1,422,441 $ (8,465) $ 361,082 $ (24,380) $ 11,993 $ (69,637)
Comprehensive (loss):                    
Net income/(loss) (533,017)           (533,017)      
Other comprehensive income/(loss) 18,878               18,878  
Total comprehensive (loss)/income $ (514,139)           (533,017)   18,878  
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-13 [Member]                  
Conversion of preferred stock to common stock (in shares)     (522,000) 1,043,000            
Conversion of preferred stock to common stock $ 0   $ (40,633) $ 11 10,395         30,227
Cash dividends declared on common shares (36,251)           (36,251)      
Cash dividends declared on preferred shares (313)           (313)      
Treasury stock purchased (in shares)       (14,000)            
Treasury stock purchased (473)           0     (473)
Forfeited shares (in shares)       (91,000)            
Forfeited shares 0       (1,570) 2,727       (1,157)
Exercise of stock options (in shares)       37,000            
Exercise of stock options 664           (465)     1,129
Restricted stock grants (in shares)       314,000            
Restricted stock grants 0       (4,121) (5,234)       9,355
Stock-based compensation 4,727         4,727        
Other, net (in shares)       (41,000)            
Other, net (626)       94   0     (720)
Ending balance, preferred stock (in shares) at Dec. 31, 2020     0              
Ending balance, common stock (in shares) at Dec. 31, 2020       50,833,000            
Ending balance at Dec. 31, 2020 1,187,773   $ 0 $ 528 1,427,239 (6,245) (233,344)   30,871 (31,276)
Comprehensive (loss):                    
Net income/(loss) 118,664           118,664      
Other comprehensive income/(loss) (34,114)               (34,114)  
Total comprehensive (loss)/income 84,550           118,664   (34,114)  
Cash dividends declared on common shares (24,553)           (24,553)      
Treasury stock purchased (in shares)       (2,500,000)            
Treasury stock purchased (68,712)                 (68,712)
Forfeited shares (in shares)       (113,000)            
Forfeited shares 0       90 2,644 0     (2,734)
Exercise of stock options (in shares)       20,000            
Exercise of stock options 417       0 0 (150)     567
Restricted stock grants (in shares)       476,000            
Restricted stock grants 0       (3,898) (9,625)       13,523
Stock-based compensation 4,170         4,170        
Other, net (in shares)       (49,000)            
Other, net $ (1,210)       14         (1,224)
Ending balance, preferred stock (in shares) at Dec. 31, 2021     0              
Ending balance, common stock (in shares) at Dec. 31, 2021 48,667,110     48,667,000            
Ending balance at Dec. 31, 2021 $ 1,182,435   $ 0 $ 528 1,423,445 (9,056) (139,383)   (3,243) (89,856)
Comprehensive (loss):                    
Net income/(loss) 92,533           92,533      
Other comprehensive income/(loss) (177,809)               (177,809)  
Total comprehensive (loss)/income (85,276)           92,533   (177,809)  
Cash dividends declared on common shares (24,527)           (24,527)      
Treasury stock purchased (in shares)       (4,485,000)            
Treasury stock purchased (124,519)                 (124,519)
Forfeited shares (in shares)       (98,000)            
Forfeited shares 0       189 2,560       (2,749)
Exercise of stock options (in shares)       12,000            
Exercise of stock options 270           (51)     321
Restricted stock grants (in shares)       328,000            
Restricted stock grants 0       537 (9,440)       8,903
Stock-based compensation 7,338         7,338        
Other, net (in shares)       (63,000)            
Other, net $ (1,659)       12         (1,671)
Ending balance, preferred stock (in shares) at Dec. 31, 2022     0              
Ending balance, common stock (in shares) at Dec. 31, 2022 44,361,222     44,361,000            
Ending balance at Dec. 31, 2022 $ 954,062   $ 0 $ 528 $ 1,424,183 $ (8,598) $ (71,428)   $ (181,052) $ (209,571)